Recent News Releases
Recent News Releases
HAEGARDA® is now available in all of Canada for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients
HAEGARDA® is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
CSL continues to provide medicines to patients around the world.
CSL Named as One of the World’s Best Employers
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation
“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies
CSL Behring and SAB Therapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic
King of Prussia, Pa. and Sioux Falls, S.D., April 8, 2020
COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology,
on-track for clinical evaluation as early as summer
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
Osaka, JAPAN, and King of Prussia, PA, USA
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Our Offer To Help Battle Coronavirus
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.
HAEGARDA® is now available in the province of Québec for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients
HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Now approved by Health Canada: Hizentra®
Now approved by Health Canada: Hizentra® (Subcutaneous Immunoglobulin [Human] 20% Liquid) for the Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for maintenance therapy
Lifesaving Medicines Donated For Patients In The Developing World
Ottawa – CSL Behring has shipped more than 10 million international units (IUs) of its medicines to treat hemophilia A to the WFH Global Alliance for Progress (GAP)Program in recognition of World Hemophilia Day.
Press Release Archive
If you are interested in global news from CSL Behring, please visit our Global Press Releases.